Skip to main content

Table 2 Comparison of baseline characteristics of ESCC patients based on OPS in training set

From: Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma

  OPS 0 (85, %) OPS 1 (124, %) OPS 2 (52, %) OPS 3 (15, %) P value
Age (years, ≤60/> 60) 54(63.5)/31(36.5) 74(59.7)/50(40.3) 25(48.1)/27(51.9) 11(73.3)/4(26.7) 0.205
Gender (male/female) 58(68.2)/27(31.8) 81(65.3)/43(34.7) 39(75.0)/13(25.0) 10(66.7)/5(33.3) 0.660
Tumor length (cm, ≤3.0/> 3.0) 34(40.0)/51(60.0) 40(32.3)/84(67.7) 9(17.3)/43(82.7) 1(6.7)/14(93.3) 0.007
Tumor location (upper/middle/lower) 4(4.7)/36(42.4)/45(52.9) 8(6.5)/57(46.0)/59(47.5) 4(7.7)/22(42.3)/26(50.0) 1(6.7)/7(46.7)/7(46.7) 0.984
Vessel invasion (no/yes) 77(90.6)/8(9.4) 103(83.1)/21(16.9) 43(82.7)/9(17.3) 8(53.3)/7(46.7) 0.004
Perineural invasion (no/yes) 76(89.4)/9(10.6) 94(75.8)/30(24.2) 39(75.0)/13(25.0) 10(66.7)/5(33.3) 0.041
Differentiation (well/moderate/poor) 15(17.6)/61(71.8)/9(10.6) 15(12.1)/81(65.3)/28(22.6) 9(17.3)/36(69.2)/7(13.5) 2(13.3)/6(40.0)/7(46.7) 0.025
TNM stage (I/II/III) 25(29.4)/39(45.9)/21(24.7) 45(36.3)/34(27.4)/45(36.3) 8(15.4)/17(32.7)/27(51.9) 1(6.7)/4(26.7)/10(66.7) < 0.001
Adjuvant treatment (no/yes) 65(76.5)/20(23.5) 84(67.7)/40(32.3) 38(73.1)/14(26.9) 11(73.3)/4(26.7) 0.576
GPS (0/1/2) 85(100)/0(0)/0(0) 97(78.2)/27(21.8)/0(0) 0(0)/42(80.8)/10(19.2) 0(0)/0(0)/15(100) < 0.001
SIS (0/1/2) 52(61.2)/28(32.9)/5(5.9) 74(59.7)/41(33.1)/9(7.2) 14(26.9)/35(67.3)/3(5.8) 0(0)/14(93.3)/1(6.7) < 0.001
PNI (≤47.5/> 47.5) 13(15.3)/72(84.7) 58(46.8)/66(53.2) 37(71.2)/15(28.8) 15(100)/0(0) < 0.001
SII (≤558/> 558) 45(52.9)/40(47.1) 50(40.3)/74(59.7) 22(42.3)/30(57.7) 1(6.7)/14(93.3) 0.008
  1. ESCC Esophageal squamous cell carcinoma, OPS Osaka prognostic score, GPS Glasgow prognostic score, SIS Systemic inflammation score, PNI Prognostic nutritional index, SII Systemic immune-inflammation index, TNM Tumor node metastasis